Peptide-Based PROTAC Technology Services

Name: Peptide-Based PROTAC Technology Development
Brand: BOC Sciences

Peptide-based PROTACs offer a powerful route for degrading proteins that are difficult to modulate with conventional small molecules, especially targets driven by extended binding interfaces, shallow pockets, or protein–protein interactions. BOC Sciences provides integrated peptide-based PROTAC technology development services covering target and ligand feasibility assessment, peptide warhead discovery, E3-recruiting peptide strategy design, linker engineering, synthesis, degradation validation, developability screening, and candidate optimization. By addressing the practical bottlenecks that matter most in peptide degrader programs—cellular uptake, proteolytic stability, ternary complex formation, selectivity, and delivery—we help clients move from concept to data-backed candidates with greater efficiency and scientific confidence.

Services

BOC Sciences' Comprehensive Peptide-Based PROTAC Development Services

Target Feasibility and Degradation Strategy Assessment We review target biology, subcellular localization, degradation rationale, known binding motifs, and structural accessibility to determine whether a peptide-based degrader is technically and strategically justified for your program. Target protein assessment Protein interface and motif analysis Degradation feasibility review Early project risk identification
Peptide Warhead Discovery and Optimization We help clients identify and optimize target-binding peptides suitable for degrader construction, with attention to affinity, selectivity, conjugation tolerance, sequence liabilities, and downstream developability. Peptide ligand for target protein Binder sequence refinement Conjugation-site compatibility assessment Stability-oriented sequence optimization
E3-Recruiting Module Design Our team designs E3 engagement strategies that fit the biological and architectural demands of peptide-based PROTACs. We support both peptide-driven and hybrid recruitment concepts to improve degradation productivity while keeping construct complexity manageable. Peptide design for E3 ubiquitin ligase E3 ligase ligand selection strategy Recruiter compatibility analysis Architecture recommendation for CRBN-, VHL-, or alternative ligase-oriented concepts
Rational Peptide-PROTAC Design and Modeling We create construct designs that integrate peptide warhead geometry, E3 recruitment, linker composition, and conjugation orientation into a coherent degradation hypothesis. This stage is especially important for avoiding designs that bind well but fail to form productive ternary complexes. PROTAC design services Molecular docking for protein-ligand interactions Ternary complex hypothesis generation Negative-control design recommendations
Linker Engineering and Construct Optimization We refine linker length, flexibility, attachment site, and physicochemical profile to improve spatial presentation, reduce steric mismatch, and support more effective degradation performance in relevant assay systems. Linker design and optimization services Peptide-compatible linker selection Conjugation orientation optimization Focused analog strategy planning
Synthesis and Analytical Characterization We provide synthesis support for peptide-based PROTAC constructs and focused analog series, with analytical confirmation that helps clients move quickly into activity testing and design iteration. Peptide-PROTAC synthesis Sequence and conjugate purity confirmation Focused analog preparation Batch comparison for structure–activity analysis
Ternary Complex and Degradation Activity Evaluation Our biological evaluation workflow is designed to answer the questions that matter most in peptide degrader programs: does the construct enter cells, does it engage the target, does it form a productive ternary complex, and does it trigger selective target loss? PROTAC ternary complex assay In vitro degradation evaluation Western blot and cellular degradation readouts Potency, selectivity, and mechanistic validation
Developability, Delivery, and Advancement Support Because peptide-based PROTAC performance is closely tied to exposure and formulation behavior, we evaluate the developability profile alongside activity data to identify practical next-step candidates. PROTAC delivery strategy support Serum stability and permeability assessment Intracellular exposure optimization In vivo evaluation planning and execution

Are These Challenges Slowing Down Your Peptide-Based PROTAC Program?

Limited access to high-affinity peptide binders for challenging intracellular proteins
Difficulty balancing peptide binding potency with membrane permeability and intracellular exposure
Rapid proteolytic degradation or poor serum stability of linear peptide constructs
Uncertainty in choosing between peptide- or small-molecule-based E3 recruitment strategies
Weak or nonproductive ternary complex formation despite strong binary binding
Poor translation from biochemical binding to cellular degradation performance
Delivery constraints for large or polar peptide-containing degraders

Tell Us Your Project

Share your target, peptide concept, or existing data, and our scientists will help define a practical peptide-PROTAC development strategy.

Submit Inquiry

Challenge Solving

Our Solutions for Peptide-Based PROTAC Development Challenges

Peptide-based PROTAC programs demand more than standard bifunctional degrader design. We combine peptide engineering, degrader design logic, and multi-parameter optimization to help clients solve the issues most likely to limit project success.

Solution for Peptide Warhead Discovery We evaluate target tractability from a peptide degrader perspective, focusing on accessible binding surfaces, motif recognition opportunities, intracellular localization, and degradation rationale. For projects requiring peptide binders, we support binder concept generation, sequence optimization, and structure-guided refinement to create peptide warheads with stronger target engagement and better compatibility with degrader design.
Solution for E3 Recruitment and Molecular Architecture We design peptide-based PROTAC architectures by systematically considering target-binding peptide format, E3 ligase recruitment strategy, linker composition, conjugation orientation, and spatial geometry. Whether your program favors peptide-mediated E3 engagement or a hybrid design using established E3 ligands, we optimize the construct to improve ternary complex productivity and degradation efficiency.
Solution for Stability, Permeability, and Delivery Peptide-containing degraders often fail because the construct cannot reach or persist at the intracellular site of action. We address this risk through sequence stabilization strategies, cyclization or stapling concepts when appropriate, conjugation-site control, physicochemical tuning, and delivery-oriented optimization designed to improve exposure without compromising degradation function.
Solution for Data-Driven Candidate Advancement We integrate synthesis, ternary complex characterization, degradation testing, and developability evaluation to identify the most promising constructs early. By interpreting degradation data together with permeability, stability, solubility, and exposure trends, we help clients prioritize candidates with more realistic downstream value.

Build Peptide Degraders with a Trusted TPD Partner

BOC Sciences helps clients design peptide-based PROTAC programs around real development constraints, not just theoretical binding concepts. From peptide motif selection to degradation validation and delivery-oriented optimization, we provide flexible support tailored to the biology and chemistry of your target.

Talk to Our Experts

Client Solutions

Our Peptide-Based PROTAC Solutions Support Diverse R&D Teams

Discovery Biology Teams

For teams working on difficult intracellular targets, signaling adaptors, or protein–protein interactions, we provide peptide degrader strategies that can open routes unavailable to conventional inhibitor programs.

Peptide Therapeutics Groups

If your team already understands peptide sequence design but needs targeted degradation expertise, we help convert peptide binders into degrader constructs with clearer E3 engagement logic and stronger validation workflows.

Biotechnology Companies

Biotech programs often need fast proof-of-concept data to support platform value, pipeline differentiation, or partnering discussions. Our modular services help generate actionable peptide-PROTAC data efficiently without forcing a one-size-fits-all workflow.

Pharmaceutical Research Units

For pharma teams exploring hard-to-drug targets or next-generation degrader modalities, we provide structured development support from feasibility assessment through construct optimization and candidate prioritization.

Get a Quote

Workflow

End-to-End Peptide-Based PROTAC Development Workflow

01

Project Intake and Technical Scoping

We review your target, existing binder data, peptide concept, disease biology, and key success criteria to define the most suitable peptide-PROTAC development path.

02

Target and Peptide Feasibility Analysis

We assess target accessibility, degradation rationale, peptide-binding opportunities, recruiter options, and likely developability risks before design begins.

03

Construct Design and Modeling

We generate design concepts covering peptide warhead selection, E3 recruitment, linker geometry, conjugation positions, and control-molecule strategy.

04

Synthesis and Analytical Confirmation

Selected peptide-based PROTACs and focused analogs are synthesized and analytically characterized to ensure readiness for downstream evaluation.

05

Ternary Complex and Degradation Validation

We test target engagement, ternary complex formation, degradation efficiency, selectivity, and mechanistic dependence in relevant biochemical and cellular systems.

06

Multi-Parameter Optimization

Based on data trends, we refine peptide sequence, recruiter choice, linker architecture, and physicochemical properties to improve overall candidate quality.

07

Developability and Delivery Assessment

We evaluate stability, permeability, intracellular exposure, and delivery-related constraints to identify the constructs most likely to succeed in advanced studies.

08

Candidate Recommendation and Data Package Delivery

We deliver prioritized constructs, supporting datasets, interpretation, and optimization recommendations to guide the next stage of your peptide degrader program.

Advantages

Why Peptide-Based PROTACs Matter for Challenging Targets?

Expands Reach Beyond Classic Small-Molecule Binding Pockets

Peptide warheads can be tailored to broader protein surfaces and interaction motifs, creating new entry points for targets that are otherwise difficult to drug.

Provides Higher Design Flexibility

Sequence-level tuning makes it possible to optimize affinity, selectivity, conjugation position, and stability in a more modular way than many purely small-molecule approaches.

Supports Novel Biology Exploration

Peptide-based degraders are especially valuable in exploratory programs where the goal is to test whether selective protein removal can reveal biology that inhibition cannot.

Creates Opportunities for Hybrid Modality Design

Peptide binders can be combined with established degrader principles, delivery concepts, and recruiter strategies to build differentiated next-generation degradation platforms.

Applications

Application Areas Supported by Our Peptide-Based PROTAC Platform

Oncology and Transcriptional Regulation

Targets driven by protein–protein interactions or extended interfaces
Transcription factors, co-regulators, and scaffold proteins with limited small-molecule tractability
Programs seeking degradation rather than occupancy-based inhibition
Resistant or pathway-redundant oncology targets requiring deeper pathway suppression

Neurodegeneration and Protein Aggregation Biology

Misfolded or aggregation-prone proteins with limited conventional druggability
Targets where selective protein removal is more informative than enzymatic inhibition
Mechanism-focused discovery programs for tauopathies and related disorders
Early-stage degrader concepts requiring sequence-based targeting hypotheses

Immunology and Signaling Pathways

Adaptor proteins and signaling mediators with difficult binding topologies
Intracellular pathway regulators where transient occupancy may be insufficient
Programs evaluating selective degradation as a route to pathway rebalancing
Research-stage targets needing rapid feasibility testing

Platform Innovation and Modality Expansion

Peptide degrader platform development
Head-to-head comparison of peptide and small-molecule warheads
Novel recruiter exploration supported by virtual screening
Hybrid targeted degradation concepts for emerging modality pipelines

Case Study

Client Success Stories: Peptide-Based PROTAC Technology Development

Project Background

A biotech client had identified a 14-residue helical peptide that disrupted a transcription-associated protein complex but did not achieve durable cellular pathway suppression. The client wanted to test whether converting the binder into a peptide-based PROTAC could produce deeper target knockdown in cell models and generate a stronger proof-of-concept package for a difficult nuclear target.

Our Support

We first evaluated the peptide's binding region, solvent exposure, and linker attachment tolerance, then designed three construct families that varied in recruiter strategy, linker flexibility, and N-terminal versus side-chain conjugation orientation. To address poor intracellular performance risk, we compared the original linear peptide with a conformationally constrained analog set and introduced a stability-oriented sequence refinement plan before full degrader assembly. Across 24 synthesized constructs, 7 showed measurable cellular target reduction, and 3 achieved reproducible degradation with clear dose response. The top construct delivered the best balance of degradation depth, selectivity, and serum stability, giving the client a practical lead architecture rather than a single isolated hit.

Project Outcome

The client obtained a prioritized peptide-PROTAC series, mechanistic validation data, and a defined optimization roadmap focused on permeability enhancement and exposure improvement, enabling the program to move into a more data-driven lead refinement stage.

Project Background

An innovative research team was exploring a protein associated with intracellular aggregation biology and had an initial cyclic peptide binder with encouraging biochemical affinity but weak cell-based activity. Their key question was whether a peptide-based PROTAC approach could preserve target recognition while improving functional protein clearance in neuronal cell models.

Our Support

We began by mapping feasible conjugation positions on the cyclic peptide and comparing two E3 engagement options with distinct linker exit vectors. Because early constructs suffered from limited degradation despite strong binding, we used an iterative strategy combining linker redesign, polarity reduction, and cell-entry-oriented construct tuning. We also profiled ternary complex behavior and cellular degradation side by side so that nonproductive designs could be removed quickly. In total, we designed 31 constructs over multiple rounds, narrowed the set to 5 advanced candidates, and identified 1 lead with markedly improved target reduction, acceptable stability in the project assay window, and a cleaner selectivity pattern than the first-generation designs.

Project Outcome

The client received a lead candidate, structure–activity insights explaining why earlier designs failed, and a clear next-step package centered on delivery enhancement and model expansion, substantially reducing uncertainty for the next phase of the program.

Why Choose Us

Why Choose BOC Sciences for Your Peptide-Based PROTAC Project?

Cross-Disciplinary Peptide and Degrader Expertise

We combine peptide design logic, targeted degradation strategy, and assay-driven optimization to support complex programs more effectively.

Design Built Around Real Failure Modes

Our workflow is structured to address the issues most likely to derail peptide-based PROTACs, including poor uptake, weak ternary complex productivity, and insufficient stability.

Flexible Service Modules

Clients can engage us for a full development workflow or for selected stages such as peptide design, linker optimization, synthesis, or degradation validation.

Mechanism-Oriented Evaluation Strategy

We do not stop at binary binding. Our studies are designed to explain whether degradation works, why it works, and which design variables matter most.

Actionable Optimization Outputs

We provide prioritized constructs, interpretable data packages, and next-step recommendations to accelerate internal decision-making.

Support for Emerging Degrader Modalities

Our experience across targeted protein degradation formats helps clients position peptide-based PROTACs within broader modality and portfolio strategies.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

What is peptide-based PROTAC technology?

Peptide-based PROTAC technology is a bifunctional molecular strategy built on the principle of targeted protein degradation. It typically consists of three core components: a peptide sequence that specifically recognizes the target protein, an E3 ligase-recruiting ligand, and a linker that connects the two. By simultaneously engaging the target protein and an E3 ubiquitin ligase, this type of molecule promotes ubiquitination and subsequent degradation of the target protein, thereby enabling functional modulation. Compared with conventional small-molecule inhibitors, peptide-based PROTACs are particularly attractive for targets that lack well-defined binding pockets or rely on protein-protein interaction interfaces, making them an important direction in the evolving field of targeted protein degradation.

What are the key development advantages of peptide-based PROTACs?

A major advantage of peptide-based PROTACs lies in their ability to combine the high recognition specificity of peptides for protein-protein interaction interfaces with the protein degradation mechanism of PROTACs. This creates new development opportunities for targets that are difficult to modulate effectively with traditional small molecules. For drug developers, this can translate into broader target coverage and deeper mechanistic validation, especially for transcription factors, scaffold proteins, and signaling pathway nodes. BOC Sciences can support these programs through integrated services spanning peptide sequence design, linker optimization, molecular construction, and early-stage screening, helping clients advance peptide-based PROTAC discovery and optimization more efficiently.

Which drug development targets are suitable for peptide-based PROTACs?

Peptide-based PROTACs are particularly well suited for target classes where ligand discovery is challenging, conventional small-molecule binding pockets are absent or poorly defined, and key recognition motifs or protein-protein interaction sites are known. In many development programs, the central question is not simply whether a target can be bound, but whether a viable degradation strategy can be established. In this context, peptides can serve as highly selective recognition elements that enable the recruitment of the ubiquitination machinery to the target protein. As a result, peptide-based PROTACs are increasingly used to explore high-value but difficult-to-drug targets and to strengthen both pharmacological insight and pipeline differentiation.

What are the biggest challenges in peptide-based PROTAC development?

The main challenges in peptide-based PROTAC development usually fall into three areas. First, the peptide ligand must bind the target protein with sufficient stability and specificity. Second, the linker design must balance spatial arrangement, E3 ligase recruitment efficiency, and overall molecular activity. Third, the full construct must show functional performance that can be systematically optimized in biologically relevant systems. Many projects do not fail because the concept is invalid, but because the individual modules do not work together effectively. Based on target characteristics and project goals, BOC Sciences can assist with candidate sequence design, linker strategy evaluation, structure-activity relationship studies, and functional screening to help reduce trial-and-error and improve optimization efficiency.

Why is the market paying attention to peptide-based PROTAC technology?

Continued market interest in peptide-based PROTACs is driven by their potential to expand the scope of targeted protein degradation. They retain the mechanistic advantage of PROTACs by enabling removal of a target protein rather than simple inhibition, while also leveraging the programmable recognition properties of peptides to address difficult targets. For drug development companies, the value of this technology extends beyond candidate discovery alone. It also contributes to platform building, more effective target validation, and pipeline differentiation. For these reasons, peptide-based PROTACs are increasingly viewed as a strategically important technology area in innovative drug discovery and development.